홈 > 시장보고서 > 의약품 > 암

시장보고서

상품코드

1297799

세계의 신장암 및 신세포암 치료제 시장(2023-2030년)

Global Kidney Cancer and Renal Cell Carcinoma Drugs Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

신장암 및 신세포암 치료제 세계 시장은 2022년 56억 달러, 2030년에는 89억 달러에 달할 것으로 예상되며, 수익성 있는 성장을 보일 것으로 전망됩니다. 세계 신장암 및 신세포암 치료제 시장은 예측 기간(2023-2030년) 동안 6.3%의 CAGR을 보일 것으로 예상됩니다.

신장암 치료 전략 및 신약 개발은 제약회사 및 연구기관으로부터 많은 자금을 지원받고 있습니다. 이러한 지속적인 연구 개발 활동으로 인해 더욱 진보된 강력한 약물이 시장에 출시되어 향후 시장 확대에 박차를 가할 것으로 예상됩니다.

시장 역학

활동적인 주요 기업들은 예측 기간 동안 세계 신장암 및 신세포암 치료제 시장의 성장을 촉진

2022년 10월 신장암 치료제 포티브다(Fotivda)의 FDA 승인을 앞두고 아베오 온콜로지(Aveo Oncology)가 변화를 꾀하고 있으며, LG화학의 인수로 포티브다와 아베오의 다른 암 후보물질의 개발을 더욱 성공적으로 이끌 계획입니다. 아베오는 지난 3월 FDA로부터 재발성 또는 저항성 진행성 신세포암 3차 치료제로 예상치 못한 승인을 받은 포티브다 외에도 3개의 항암제 후보물질을 보유하고 있습니다.

아베오는 최근 2028년에 만료되는 포티바의 특허를 2039년까지 연장할 수 있다는 사실을 발견해 LG화학에 더 유리하게 작용하고 있습니다.

맞춤형 의료의 개척으로 신장암 및 신세포암 치료제 시장 성장 기회 제공

신장암의 유전적, 분자적 측면에 대한 이해도가 높아지면서 개인 맞춤형 의료기술이 탄생했습니다. 맞춤형 치료 계획을 수립하기 위해 유전자 검사 및 바이오마커 분석은 종양의 특정 돌연변이 및 이상을 탐지하는 데 도움을 주고 있습니다. 특정 유전적 결함을 타깃으로 하는 약물은 개인 맞춤형 치료에 초점을 맞추기 때문에 수요가 높으며, 시장 확대를 촉진하고 있습니다.

신장암과 RCC에 관여하는 특정 분자 표적에 특이적으로 작용하는 표적치료제는 맞춤의료로 인해 가능해졌습니다. 면역관문억제제, 티로신 키나아제 억제제(TKI) 등 이러한 의약품은 종양의 발생과 생존에 필수적인 특정 분자와 경로를 차단하도록 만들어졌습니다.

COVID-19 영향 분석

COVID-19의 대유행은 신장암 및 신세포암 치료제 시장에 큰 영향을 미쳤습니다. 전염병은 전 세계 물류 및 공급망에 영향을 미쳤으며, 특히 신장암 및 신세포암 치료에 필요한 약품의 공급에 어려움을 겪었습니다. 중요한 의약품의 안정적인 공급을 유지하기 위한 노력에도 불구하고 때때로 부족하거나 배송이 지연되고 있습니다. 또한, 국경 폐쇄 및 운송 제한으로 인해 의약품의 수출입이 방해받고 있으며, 일부 지역에서는 의약품 접근이 불가능할 수도 있습니다.

2023년 현재 COVID-19 상황이 회복되어 모든 환자가 의료 시설에 접근할 수 있게 되면서 신장암 및 신세포암 약품에 대한 수요가 증가하고 있습니다.

러시아-우크라이나 분쟁 분석

러시아-우크라이나 분쟁이 신장암 및 신세포암 치료제 시장에 미치는 영향은 복잡하고 다면적입니다. 분쟁은 의료 시스템에 부담을 줄 수 있으며, 암 치료와 같은 전문적인 치료에서 자원과 초점을 빼앗을 수 있습니다. 최상의 치료를 제공하기 위해 병원과 의료 시설에 특수 약물에 대한 접근과 같은 문제가 발생할 수 있습니다.

Market Overview

The Global Kidney Cancer and Renal Cell Carcinoma Drugs Market reached US$ 5.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 8.9 billion by 2030. The global kidney cancer and renal cell carcinoma drugs market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030).

The development of novel medications and kidney cancer treatment strategies is receiving significant funding from pharmaceutical corporations and research organizations. The introduction of additional cutting-edge and potent medications to the market is anticipated to result from this ongoing research and development activity, spurring future expansion.

Market Dynamics

Active Major Players Are Boosting The Global Kidney Cancer And Renal Cell Carcinoma Drugs Market Growth During The Forecast Period.

In October 2022, on the approach to receiving FDA approval for its kidney cancer medication Fotivda, Aveo Oncology took a diversion. LG Chem now intends to have better success developing Fotivda and Aveo's other cancer candidates due to Aveo's acquisition of LG Chem. Aveo has three other cancer candidates in addition to Fotivda, which was unexpectedly approved by the FDA in March for the third-line treatment of advanced renal cell carcinoma that has relapsed or is resistant.

Aveo recently found that its patent on Fotivda, set to expire in 2028, could really be extended all the way to 2039, making it more desirable for LG Chem.

The Development Of Personalized Medicines Provides Kidney Cancer And Renal Cell Carcinoma Drug Market Growth Opportunities.

Personalized medicine techniques have been created as a result of our growing understanding of the genetic and molecular aspects of kidney cancer. In order to develop customized treatment plans, genetic testing, and biomarker analyses help detect certain mutations or abnormalities in tumors. Drugs that target particular genetic defects are in high demand due to the focus on personalized therapy, which is propelling market expansion.

Targeted medicines that specifically tackle particular molecular targets involved in kidney cancer and RCC have been made possible by personalized medicine. These medications, such as immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), are made to block particular molecules or pathways that are essential for the development and survival of tumors.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the kidney cancer and renal cell carcinoma drugs market. The pandemic has impacted worldwide logistics and supply chains, which has caused disruptions in the accessibility of drugs, especially those required to treat kidney cancer and RCC. Despite efforts to keep a consistent supply of important pharmaceuticals, there have occasionally been shortages and delays in their delivery. Additionally, border closures and limits on transportation may have hindered the import and export of pharmaceuticals, which could have hampered access in some regions.

As of 2023, the COVID-19 situation is recovering and all patients can access the healthcare facilities leading to increasing demand for kidney cancer and renal cell carcinoma drugs.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the kidney cancer and renal cell carcinoma drugs market is complex and multifaceted. The dispute may put a strain on the healthcare system, taking resources and focus away from specialized treatments like cancer therapy. Providing the best care may present issues for hospitals and healthcare facilities, including access to specialized medications.

Segment Analysis

The global kidney cancer and renal cell carcinoma drugs market is segmented based on product, end-user, distribution channel, and region.

The Everolimus Segment Is Expected To Hold A Position In The Market Over The Forecast Period.

The Everolimus segment accounted for one of the highest market stake accounting for approximately 22.3% of the kidney cancer and renal cell carcinoma drugs market in 2022. Everolimus works by inhibiting the mTOR pathway, which is involved in regulating cell growth, proliferation, and angiogenesis (the formation of new blood vessels). By inhibiting mTOR, Everolimus helps slow down the growth of cancer cells and prevents the formation of new blood vessels that supply nutrients to the tumor. Everolimus can be used as a single agent or in combination with other drugs for the treatment of advanced RCC.

Geographical Analysis

An Increasing Number Of Patients With Kidney Cancer, FDA Approvals, And Advancement In Kidney Cancer And Renal Cell Carcinoma Drugs Dominate The European Region.

Europe is expected to dominate the kidney cancer and renal cell carcinoma drugs market, accounting for around 27.9% of this market. Different European nations have different rates of kidney cancer, particularly renal cell carcinoma (RCC). With more than 115,000 cases identified each year and 49,000 fatalities, kidney cancer is the fifth most prevalent malignancy in Europe.

In Europe, there are more people over the age of 65 than anywhere else in the world. The incidence of kidney cancer tends to rise with age, and the aging population adds to the disease's overall prevalence.

Competitive Landscape

The major global players in the market include: Roche Inc, GlaxoSmithKline Plc., Active Biotech Ab., Heidelberg Pharma AG, Inc., Bristol-Myers Squibb, Eisai, Exelixis, Novartis AG, Amgen, and Bayer AG among others.

Why Purchase the Report?

To visualize the global kidney cancer and renal cell carcinoma drugs market segmentation based on the product, end-users, distribution channel, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous kidney cancer and renal cell carcinoma drugs market-level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global kidney cancer and renal cell carcinoma drugs market report would provide approximately 61 tables, 63 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by End-users
3.3. Snippet by Distribution Channel
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing incidences of kidney and RCC cases
- 4.1.2. Restraints
  - 4.1.2.1. Side effects associated with These Drugs
- 4.1.3. Opportunity
  - 4.1.3.1. Research and development
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.1.2. Market Attractiveness Index, By Product
9.2. Bevacizumab*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Everolimus
9.4. Cabozantinib
9.5. Axitinib
9.6. Sorafenib
9.7. Temsirolimus
9.8. Sunitinib
9.9. Pazopanib

10. By End-users

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 10.1.2. Market Attractiveness Index, By End-users
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Specialty Clinics
10.5. Others

11. By Distribution Channel

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.6.1. The U.S.
  - 12.2.6.2. Canada
  - 12.2.6.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.6.1. Germany
  - 12.3.6.2. The U.K.
  - 12.3.6.3. France
  - 12.3.6.4. Italy
  - 12.3.6.5. Spain
  - 12.3.6.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.6.1. Brazil
  - 12.4.6.2. Argentina
  - 12.4.6.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.6.1. China
  - 12.5.6.2. India
  - 12.5.6.3. Japan
  - 12.5.6.4. Australia
  - 12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. Roche Inc*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. GlaxoSmithKline Plc.
14.3. Active Biotech Ab
14.4. Heidelberg Pharma AG, Inc.
14.5. Bristol-Myers Squibb
14.6. Eisai
14.7. Exelixis.,
14.8. Novartis AG
14.9. Amgen
14.10. Bayer AG

LIST NOT EXHAUSTIVE

15. Appendix

15.1. About Us and Services
15.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,294,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 7,017,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,358,000

※ 부가세 별도

세계의 신장암 및 신세포암 치료제 시장(2023-2030년)

Global Kidney Cancer and Renal Cell Carcinoma Drugs Market - 2023-2030

시장 개요

시장 역학

활동적인 주요 기업들은 예측 기간 동안 세계 신장암 및 신세포암 치료제 시장의 성장을 촉진

맞춤형 의료의 개척으로 신장암 및 신세포암 치료제 시장 성장 기회 제공

COVID-19 영향 분석

러시아-우크라이나 분쟁 분석

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

제5장 산업 분석

제6장 COVID-19 분석

제7장 러시아·우크라이나 전쟁 분석

제8장 인공 지능 분석

제9장 제품별

제10장 최종사용자별

제11장 유통 채널별

제12장 지역별

제13장 경쟁 상황

제14장 기업 개요

제15장 부록